HYPERRAB S/D Rx
Generic Name and Formulations:
Rabies immune globulin (human) 150 IU/mL; soln for IM inj; preservative-free; latex-free.
Grifols Biologicals, Inc.
Indications for HYPERRAB S/D:
Postexposure prophylaxis of rabies.
See literature. Give by IM inj preferably at the time of 1st vaccine dose; may be given through 7th day after 1st vaccine dose is given. 20 IU/kg (0.133mL/kg) once. If feasible, up to full dose should be infiltrated in area around wound and the rest into deltoid muscle of upper arm or lateral thigh muscle.
Previously immunized with rabies vaccine with a confirmed adequate rabies antibody titer: not recommended. Contains human plasma; monitor for possible infection transmission. IgA-deficiency. Thrombocytopenia or other bleeding disorders. Prior history of allergic reactions to human immunoglobulins. Have epinephrine inj available. Pregnancy (Cat.C).
Avoid live vaccines within 3 months.
Inj site reactions, mild temp elevations; rare: angioneurotic edema, rash, nephrotic syndrome, anaphylactic shock.
Single-use vial (2mL, 10mL)—1
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine